摘要:
Methods and pharmaceutical compositions for use in inhibiting calmodulin activity in a patient are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, which are administered to a patient in need of treatment of a non-estrogen dependent condition.
摘要:
Methods and pharmaceutical compositions for the treatment of dermatitis are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, which are administered to a patient suffering from dermatitis. The methods and compositions are particularly useful in the treatment of conditions characterized by hyperproliferation of keratinocytes, such as psoriasis.
摘要:
Methods and pharmaceutical compositions for reducing bone loss are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. An exemplary 3,4-diarylchroman is centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl]-7-methoxychroman). Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.
摘要:
Methods and pharmaceutical compositions for reducing bone loss are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. An exemplary 3,4-diarylchroman is centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl]-7-methoxy-chroman). Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.
摘要:
Methods and pharmaceutical compositions for the treatment of dermatitis are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, which are administered to a patient suffering from dermatitis. The methods and compositions are particularly useful in the treatment of conditions characterized by hyperproliferation of keratinocytes, such as psoriasis.
摘要:
Methods and pharmaceutical compositions for reducing bone loss are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.
摘要:
Compounds of the formula wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C; Y is of the formula or a stereoisomer thereof, wherein R1 is substituted or unsubstituted alkyl; each R2 is independently H, hydroxy, alkoxy (1-6C) or lower alkyl (1-4C); R3 is H, hydroxy, or alkoxy (1-6C); or Y is of the formula wherein each n is 1, Z is N, K comprises a substituted or unsubstituted aromatic carbocyclic or heterocyclic ring system which may optionally be spaced from the linkage position shown in formula (7) by a linker of 1-2C, or in formula (7), Z may be spaced from the carbon bonded to X by ═CR6— wherein R6 is H or linear, branded or cyclic alkyl (1-6C), R5 is H or linear, branched or cyclic alkyl, and R′ represents a cation, H or a substituted or unsubstituted alkyl group of 1-6C, promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. Also disclosed is a method to identify additional compounds which are inhibitors of enzymes in the isoprenoid scheme especially of HMG-CoA reductase which results in prenylation of proteins and in the synthesis of steroids or of inhibitors of their production which are useful in treating bone disorders.
摘要:
The present invention relates to an orthogonally-protected compound of the formula: ##STR1## wherein PG.sub.1 is a first protecting group that is unreactive to a chemistry used at another position within the compound, and that is capable of selective removal without affecting PG.sub.2 or linkage to a solid support; PG.sub.2 is a second protecting group that is unreactive to a chemistry used at another position within the compound, and that is capable of selective removal without affecting PG.sub.1 or linkage to a solid support; Y is CH.sub.2 COOH, CH.sub.2 SO.sub.2 OH, CH.sub.2 PO.sub.2 ROH, CH.sub.2 Ph--COOH, CH.sub.2 Ph--SO.sub.2 OH, or CH.sub.2 Ph--PO.sub.2 ROH; R is H or a substituted or unsubstituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; and n is 1 or 2. PG.sub.1 is preferably a carbamate group, a trityl group, or a trifluoroacetyl group; and PG.sub.2 is preferably an ester.
摘要:
There are disclosed thionated analogues of thyrotropin releasing hormone, having the formula: ##STR1## wherein, Q, W, X and Y, same or different, are oxygen or sulfur, with the proviso that at least one of Q, W, X and Y is always sulfur;Z is lower alkyl or (4-imidazolyl)methyl; and the pharmaceutically acceptable salts thereof. The disclosed compounds highly and selectively bind to TRH binding sites in animal tissues, and their utility in treating a variety of diverse physical conditions is disclosed. Pharmaceutical compositions containing the compounds are also disclosed.